The antitumorigenic mechanism of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib is still a matter of debate. Among different structurally related COX-2 inhibitors, only celecoxib was found to cause apoptosis and cell death of human lung cancer cells ( 
INTRODUCTION
Besides its anti-inflammatory and analgesic properties, the anticarcinogenic action of celecoxib, a selective inhibitor of the prostaglandin (PG)-synthesizing enzyme cyclooxygenase-2 (COX-2) (1), has gained early attention. Therefore, the US Food and Drug Administration approved celecoxib for adjuvant treatment of patients with familial adenomatous polyposis (FAP) . In this context a 6-months twice-daily treatment with 400 mg of celecoxib was shown to lead to a significant reduction in the number of colorectal polyps in patients with FAP (2) . Another study suggested celecoxib for prevention of colorectal adenomas (3) . Recent reports furthermore indicate celecoxib as treatment and preventive option for lung cancer (4-7) and to enhance the response to classical chemotherapeutics in early stage non-small cell lung cancer (NSCLC) (8). These studies have attracted particular interest given that lung cancer is worldwide the most common cancer in terms of both incidence and mortality and the response and remission rates in NSCLC patients still remains relatively low (9).
Experimental studies revealed celecoxib to exhibit a proapoptotic and tumor-regressive action in various xenograft models (10-14). However, the underlying mechanism is still controversial. Although both COX-2-dependent and -independent proapoptotic mechanisms of celecoxib have been reported, a thorough analysis indicates a significant part of celecoxib´s antitumorigenic action to occur independent of its COX-2 inhibitory function (12,15-18). In addition and in contrast to the traditional view implying a protumorigenic function of COX-2 (19,20), overexpression of COX-2 decreased proliferation and increased apoptosis of osteosarcoma cells (21) and protected rather than sensitized animals to experimental skin tumor development (22) . In line with these findings COX-2 upregulation has emerged as a proapoptotic mechanism shared by various antitumorigenic compounds (23-30). 7 After a centrifugation step, pellets were resuspended in 1 ml of a hypotonic buffer containing 20 mM HEPES, pH 7.5, 5 mM NaF, 10 µM Na 2 MoO 4 and 0.1 mM EDTA. Afterwards cells were allowed to swell on ice for 15 min, 50 µl of a 10% (w/v) Nonidet ® P-40 solution was added to each well and the solution was gently shaken. Following centrifugation of the homogenate, supernatants were carefully rinsed and nuclear pellets were resuspended in 40 µl of complete lysis buffer containing 50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton ® X-100, 10% (v/v) glycerol, 1 mM PMSF, 1 µg/ml leupeptin, 10 µg/ml aprotinin and 0.1% (w/v) SDS. Thereafter, tubes were shaken on ice for 30 min and a depris spin out was performed by centrifugation at 14.000 x g for 10 min. Supernatants were used for determination of nuclear protein by Western blot as described above.
Analysis of nuclear PPARγ
For confocal imaging of PPARγ and nuclear regions, fixed cells were incubated with a PPARγ antibody (Biomol GmbH) and a lamin A/C antibody (New England Biolabs GmbH).
Secondary antibodies were a goat anti-rabbit Alexa Fluor ® 555 labelled IgG for detection of PPARγ and a goat anti-mouse Alexa Fluor ® 488 labelled IgG for detection of lamin A/C (Life Technologies Corporation; Darmstadt, Germany). All antibodies were diluted in PBS containing 0.3% (v/v) Triton ® X-100 and 1% (v/v) bovine serum albumin.
Determination of COX-2 activity
To assess the effect of celecoxib on COX-2 activity and PG production by A549, H358 and H460 cells, two different experimental protocols were used.
In a first approach ( change, NS-398 (1 µM) or celecoxib (1 µM) were added to the cultures and the incubation was continued for another 30 min. Arachidonic acid (30 µM) was added subsequently and cells were incubated in a final volume of 300 µl for a further 15 min. Afterwards, the medium was removed and analyzed for PGE 2 , PGD 2 and 15d-PGJ 2 .
In a second approach (Fig. 4B ) experimental conditions comparable to those used for analyses of cytotoxicity and apoptosis were used. To this end, cells seeded in 24-well plates at a density of 2 x 10 5 cells per well and grown to confluence were preincubated with NS-398
RESULTS

Impact of different selective COX-2 inhibitors on apoptotic cell death
Analysis of the effects of different selective COX-2 inhibitors (coxibs) on viability and apoptosis of human lung cancer cells revealed celecoxib as the only compound to exhibit cytotoxic ( Fig. 1A ) and proapoptotic properties (Fig. 1B) . In further experiments celecoxib was
shown to cause a concentration-dependent induction of cytotoxicity (Fig. 1C) revealed toxic effects of celecoxib that became significant following a 12-h (H460) or 18-h incubation (A549, H358) with a further rapid drop of viability after a 24-h treatment (Fig. 1E ).
Impact of celecoxib on COX-2 and PPARγ expression
Next the impact of celecoxib on COX-2 and PPARγ expression was assessed in A549, H460, H358 as well as in primary tumor cells obtained from resections of brain metastases of 2 NSCLC patients. Celecoxib caused a concentration-dependent increase of both COX-2
and PPARγ protein expression in all cell lines ( Fig. 2A) . Due to the limited availability of primary tumor cells obtained from resections of brain metastases of 2 NSCLC patients, analyses were restricted to key experiments confirming an upregulation of COX-2 and PPARγ mRNA and protein at one time point (Fig. 2B) .
Additional experiments were performed to investigate the impact of the three other selective COX-2 inhibitors on COX-2 and PPARγ expression (Fig. 2C) . However, in all cell lines tested a profound, greater than 1.5-fold induction of COX-2 and PPARγ protein expression was unique for celecoxib and not shared by etoricoxib, rofecoxib and valdecoxib.
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Time-course of celecoxib-induced COX-2, PPARγ, L-PGDS expression and PG production
In each cell line, celecoxib elicited a time-dependent increased expression of COX-2 and PPARγ both at the mRNA (Fig. 3A-C , left) and protein levels ( Fig. 3A-C, right) . In addition, celecoxib treatment was associated with increased protein levels of lipocalin-type PGD synthase (L-PGDS), which catalyses the isomerization of PGH 2 to PGD 2 ( Fig. 3A-C, right) .
Further time-course experiments revealed significant increased concentrations of PGD 2 and 15d-PGJ 2 concentrations in supernatants of all cell lines within a 12-to 24-h incubation with celecoxib ( Fig. 3D , middle and right). PGE 2 levels became significantly decreased after a 2-h treatment with celecoxib in all cell lines and increased above vehicle control levels thereafter,
i.e. after 6 h in H460, 12 h H358 cells and 24 h in A549 cells (Fig. 3D, left) . Noteworthy, experiments monitoring PGD 2 levels in the cell culture media of vehicle and celecoxib-treated cells revealed a similar time-course as compared to PGE 2 with an initial drop of PGD 2 after 2 h (A549, H358) and 6 h (H460) and a subsequent increase of PGD 2 in all cell lines (Fig. 3D , middle).
Impact of celecoxib on COX-2 activity and PG production
To evaluate whether the upregulation of PG production by celecoxib is causally linked to increased COX-2 expression and thus sensitive towards inhibition of COX-2 activity, concentrations of PGs were measured in cell culture media using two different experimental settings.
In a first approach (Fig. 4A ) cells were treated with 30 µM (A549, H460) or 50 µM (H358) celecoxib for 24 h (A549), 48 h (H460) or 18 h (H358) to induce COX-2. Following a washout step, arachidonic acid was added exogenously before PGs were measured in cell culture media. In each cell line long-term incubation with celecoxib at 30-50 µM induced significant upregulations of PGE 2 , PGD 2 and 15d-PGJ 2 levels with all increases being sensitive to the selective COX-2 inhibitor NS-398 and to celecoxib (both compounds tested at 1 µM) that were added to cells 30 min prior to addition of arachidonic acid (Fig. 4A) .
In a second approach (Fig. 4B ) the levels of PGs were evaluated without exogenously added arachidonic acid. In this experimental setting which was likewise used for analyses of cytotoxicity and apoptosis, NS-398 at 1 µM was added to cells 1 h prior to celecoxib (30-50 µM) followed by a long-term (at least 18 h) coincubation with celecoxib. Collectively, these experiments ( Fig. 4B) revealed similar results as compared to the COX-2 activity assays shown in Fig. 4A in that the celecoxib-driven increase of the three PGs was likewise inhibited by NS-398 (Fig. 4B ).
Impact of COX-2 and PPARγ on celecoxib-induced apoptotic cell death
To investigate a potential involvement of COX-2 and PPARγ in celecoxib-induced apoptotic cell death, experiments using NS-398 and the PPARγ antagonist GW9662 were performed.
As shown in Table 1 , NS-398 and GW9662 inhibited both apoptosis and cell death caused by celecoxib in each cell line as well as in primary cells.
To further substantiate the role of COX-2 and PPARγ in celecoxib-induced apoptotic cell death and to exclude possible off-target effects of NS-398 and GW9662, transfection experiments were performed using siRNA targeting COX-2 and PPARγ. Celecoxib-induced DNA fragmentation and loss of viability were furthermore significantly inhibited by knockdown of COX-2 ( Fig. 5A , Table 2 ) and PPARγ (Fig. 5B, Table 2 ) using siRNA approaches.
Influence of NS-398 and GW9662 on the celecoxib-modulated expression and intracellular distribution of COX-2 and PPARγ
To elucidate a potential coordinated action of COX-2 and PPARγ, the impact of NS-398 and GW9662 on celecoxib-induced expression of COX-2 and PPARγ in total cell lysates and fractions of nuclei from A549, H460 and H358 cells was investigated.
According to Fig. 6A ,B (PPARγ in nuclei) a profound translocation of PPARγ to nuclear regions became evident when cells where treated with celecoxib for the same time periods where a substantial PG accumulation ( Fig. 3D and 4B) , apoptosis (Fig. 5 , Table 1 ) and cell death (Table 1 and 2) was observed (i.e., 24 h for A549, 48 h for H460, 18 h for H358).
As further shown in Fig. 6A (PPARγ in nuclei) the nuclear accumulation of PPARγ by celecoxib was completely abrogated by NS-398 in all 3 cell lines suggesting NS-398 to confer an inhibition of the celecoxib-induced cytosol-to-nuclear translocation of PPARγ. This finding was substantiated by confocal imaging of intracellular PPARγ that appeared more restricted to nuclear regions in cells treated with celecoxib in the absence of NS-398 (Fig. 6C ).
On the basis of the time-course experiments shown in Fig. 3A -C demonstrating COX-2 mRNA to be induced by celecoxib prior to PPARγ mRNA a possible involvement of COX-2 in the celecoxib-induced PPARγ expression was tested further. However, NS-398 did not reverse the celecoxib-induced increase of total PPARγ levels in A549 and only slightly decreased this response in H460 and H358 (Fig. 6A , PPARγ in total lysates; middle blots).
Likewise, NS-398 did not suppress but rather slightly increased celecoxib-induced total COX-2 protein levels in any cell line (Fig. 6A ).
Similar to the effect of NS-398, the PPARγ antagonist GW9662 also inhibited celecoxibinduced accumulation of PPARγ in nuclear regions (Fig. 6B) indicating PPARγ ligand crosslinking to be involved in this response. By contrast, GW9662 did not alter COX-2 levels in nuclear fractions and total cell lysates (Fig. 6B) .
In control experiments a potential, not PG-driven activation of PPARγ by celecoxib was addressed following a 2-h incubation with celecoxib. As shown in Fig. 3D , none of the analyzed PGs became elevated by celecoxib treatment within this early time frame.
According to Western blot analyses of nuclear fractions (Fig. 6D ), a 2-h treatment of cells with celecoxib was not accompanied by a translocation of PPARγ into the nuclei indicating that celecoxib does not confer direct activation of PPARγ.
Impact of exogenous PGs on nuclear and total levels of PPARγ
To further confirm a link between the celecoxib-induced elevation of COX-2-dependent PGs and subsequent PPARγ activation eventually leading to cancer cell death, the impact of exogenously added PGs on nuclear accumulation of PPARγ and apoptosis was investigated.
According to Fig. 7A , PGD 2 and 15d-PGJ 2 but not PGE 2 induced a nuclear accumulation of
PPARγ within a 4-h incubation without affecting total PPARγ expression. Upregulation of both nuclear and total PPARγ levels by PGD 2 and 15d-PGJ 2 was observed following longer incubation periods, whereas again PGE 2 was inactive in this respect (Fig. 7B ).
As expected, PGD 2 and 15d-PGJ 2 induced DNA fragmentation that was sensitive to GW9662
( Fig. 7C ).
To exclude the possibility that off-target effects rather than COX-2 inhibition confer the inhibitory action of NS-398 on PPARγ translocation closing experiments addressed the impact of NS-398 on PPARγ activation elicited by another stimulus. On the basis of the data presented in Fig. 7A -C, 15d-PGJ 2 was chosen as PPARγ activator for this purpose.
According to Fig. 7D , the PPARγ accumulation by 15d-PGJ 2 was not impaired by NS-398 thus excluding an unspecific action of the COX-2 inhibitor (Fig. 7D) .
DISCUSSION
The present study demonstrates induction of COX-2 expression followed by activation of Collectively, this is the first study to provide insights into the functional consequence of celecoxib-induced COX-2 expression and presents a hitherto unknown proapoptotic mechanism of celecoxib comprising the activation of PPARγ by de novo synthesized COX-2-derived PGs. Further studies addressing the impact of celecoxib on these parameters in vivo are suggested to better understand the antitumorigenic action of celecoxib.
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